Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | YWHAZ | P63104 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318804 | 1.00 | MEN1 (0.40) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7149962 | 1.00 | MEN1 (0.40) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL14565283 | 1.00 | MEN1 (0.40) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7150055 | 1.00 | MEN1 (0.40) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7149494 | 0.95 | MEN1 (0.45) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7151335 | 0.95 | MEN1 (0.45) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7149476 | 0.95 | MEN1 (0.45) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL10889700 | 0.95 | MEN1 (0.45) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL7155153 | 0.95 | MEN1 (0.45) | MEN1KMT2AL3MBTL1YWHAZCA2 | |
| SCHEMBL14428926 | 0.92 | MEN1 (0.37) | MEN1KMT2AL3MBTL1YWHAZCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2018089786-A1 | ATG7 INHIBITORS AND THE USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | MEN1 2795/4885KMT2A 1774/4885L3MBTL1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.